MetaCap

Immunocore (IMCR) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Windward Bio Group is the larger company by market cap ($1.45 billion vs $1.36 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMCR-11.79%WWB-14.79%
+7%-8%-22%
Nov 13, 20261 yearNov 20, 2026
IMCR-11.79%WWB-14.79%
+1%-7%-16%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMCR versus WWB key metrics
MetricIMCRWWB
Share price$26.41$24.29
Market cap$1.36B$1.45B
1-day change-0.83%+1.15%
YTD return-23.91%—
1-year return-32.88%—
5-year return-27.41%—
EPS (TTM)$-0.64$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$400.02M—
Revenue growth (YoY)+28.95%—
Net income (latest FY)$-35.51M—
Gross margin98.73%—
Operating margin-11.34%—
Net margin-8.88%—
52-week high$40.72$33.99
52-week low$25.61$18.35
Distance from 52-week high-35.13%-28.55%
Analyst consensusbuy—
Avg. price target upside+124.54%—
Average volume450.88K434.33K
Shares outstanding51.68M59.58M
Employees52433
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Immunocore

IMCR stock →

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

IMCR vs WWB FAQ

Which is bigger, Immunocore or Windward Bio Group?

Windward Bio Group (WWB) is larger, with a market capitalization of $1.45B compared with $1.36B for Immunocore (IMCR).

Are Immunocore and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons